MX2020001399A - Agentes antifungicos con actividad mejorada en ph acido. - Google Patents

Agentes antifungicos con actividad mejorada en ph acido.

Info

Publication number
MX2020001399A
MX2020001399A MX2020001399A MX2020001399A MX2020001399A MX 2020001399 A MX2020001399 A MX 2020001399A MX 2020001399 A MX2020001399 A MX 2020001399A MX 2020001399 A MX2020001399 A MX 2020001399A MX 2020001399 A MX2020001399 A MX 2020001399A
Authority
MX
Mexico
Prior art keywords
fungal
conditions
under
enfumafungin
acid
Prior art date
Application number
MX2020001399A
Other languages
English (en)
Spanish (es)
Inventor
Gonzalez David A Angulo
Original Assignee
Scynexis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63209698&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2020001399(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scynexis Inc filed Critical Scynexis Inc
Publication of MX2020001399A publication Critical patent/MX2020001399A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2020001399A 2017-08-04 2018-07-31 Agentes antifungicos con actividad mejorada en ph acido. MX2020001399A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762541370P 2017-08-04 2017-08-04
PCT/US2018/044619 WO2019028034A1 (en) 2017-08-04 2018-07-31 Antifungal agents with enhanced activity in acidic ph

Publications (1)

Publication Number Publication Date
MX2020001399A true MX2020001399A (es) 2020-08-06

Family

ID=63209698

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020001399A MX2020001399A (es) 2017-08-04 2018-07-31 Agentes antifungicos con actividad mejorada en ph acido.

Country Status (26)

Country Link
US (3) US11534433B2 (https=)
EP (3) EP4732902A2 (https=)
JP (1) JP7214714B2 (https=)
KR (1) KR102807716B1 (https=)
CN (2) CN111093655A (https=)
AU (2) AU2018309718B2 (https=)
BR (1) BR112020002290A2 (https=)
CA (1) CA3071940A1 (https=)
CY (1) CY1125690T1 (https=)
DK (1) DK3661503T3 (https=)
EA (1) EA202090445A1 (https=)
ES (1) ES2932658T3 (https=)
FI (1) FI3661503T3 (https=)
HR (1) HRP20221414T1 (https=)
HU (1) HUE060508T2 (https=)
LT (1) LT3661503T (https=)
MA (1) MA49751B1 (https=)
MD (1) MD3661503T2 (https=)
MX (1) MX2020001399A (https=)
PL (1) PL3661503T3 (https=)
PT (1) PT3661503T (https=)
RS (1) RS63746B1 (https=)
SI (1) SI3661503T1 (https=)
SM (1) SMT202200461T1 (https=)
TW (1) TWI805600B (https=)
WO (1) WO2019028034A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021016876A2 (pt) * 2019-02-27 2021-11-03 Scynexis Inc Métodos para tratar e para prevenir pneumonia por pneumocystis, métodos para tratar e para prevenir pneumonia por pneumocystis jirovecii, preparação de um medicamento para tratar ou prevenir pneumonia por pneumocystis jirovecii, e, uso de um composto
AU2020276595B2 (en) * 2019-05-16 2025-12-04 Scynexis, Inc. Antifungal Agents for Candida Auris Decolonization
WO2022140646A1 (en) * 2020-12-26 2022-06-30 Mycovia Pharmaceuticals, Inc Dosing regimen for oteseconazole

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756472A (en) 1996-01-31 1998-05-26 Merck & Co., Inc. Antifungal agent obtained from hormonema
JP5245057B2 (ja) 2006-04-03 2013-07-24 メルク・シャープ・アンド・ドーム・コーポレーション 抗真菌剤
WO2010019204A1 (en) 2008-08-12 2010-02-18 Merck Sharp & Dohme Corp. Antifungal agents
KR101686075B1 (ko) * 2008-08-12 2016-12-13 싸이넥시스, 인크. 항균제
HRP20220544T1 (hr) 2015-01-19 2022-08-05 Scynexis, Inc. Nove soli i polimorfi scy-078
MA49889A (fr) * 2017-04-10 2020-06-24 Scynexis Inc Agents antifongiques utilisés en association

Also Published As

Publication number Publication date
EP3661503B1 (en) 2022-09-07
BR112020002290A2 (pt) 2020-09-08
US20200390751A1 (en) 2020-12-17
EP4732902A2 (en) 2026-04-29
US20260000656A1 (en) 2026-01-01
JP2020529999A (ja) 2020-10-15
KR20200044823A (ko) 2020-04-29
MD3661503T2 (ro) 2023-01-31
HRP20221414T1 (hr) 2023-01-20
EA202090445A1 (ru) 2020-06-23
TW201919476A (zh) 2019-06-01
CA3071940A1 (en) 2019-02-07
FI3661503T3 (fi) 2022-12-15
HUE060508T2 (hu) 2023-03-28
AU2018309718B2 (en) 2024-07-25
MA49751B1 (fr) 2022-12-30
SMT202200461T1 (it) 2023-01-13
EP4169514B1 (en) 2026-01-28
US11534433B2 (en) 2022-12-27
ES2932658T3 (es) 2023-01-23
SI3661503T1 (sl) 2023-01-31
RS63746B1 (sr) 2022-12-30
CN118542868A (zh) 2024-08-27
CY1125690T1 (el) 2026-02-25
LT3661503T (lt) 2022-12-12
EP4169514A1 (en) 2023-04-26
PT3661503T (pt) 2022-12-13
KR102807716B1 (ko) 2025-05-13
PL3661503T3 (pl) 2023-01-09
EP3661503A1 (en) 2020-06-10
CN111093655A (zh) 2020-05-01
WO2019028034A1 (en) 2019-02-07
US20230364067A1 (en) 2023-11-16
MA49751A (fr) 2020-06-10
AU2024227501A1 (en) 2024-11-07
EP4169514C0 (en) 2026-01-28
JP7214714B2 (ja) 2023-01-30
TWI805600B (zh) 2023-06-21
AU2018309718A1 (en) 2020-02-27
DK3661503T3 (da) 2022-12-12

Similar Documents

Publication Publication Date Title
CU20150163A7 (es) DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET
TR201904455T4 (tr) Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları.
MX2019014980A (es) 3-fenilisoxazolin-5-carboxamidas de acidos y esteres tetrahidro y dihidrofuranocarboxilicos con efecto herbicida.
PE20151727A1 (es) Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-ciano-metil)-amidas sustituidas inhibidores de catepsina c
MX2016009666A (es) Suministro topico de composiciones para la piel que tienen ph bajo.
CL2022001439A1 (es) Combinación de antagonista del receptor lpa1 de azetidina con pirfenidona y, o nintedanib.
ES3057783T3 (en) Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
EA202090860A1 (ru) Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn
EA201691808A8 (ru) Кортикостероидные композиции для местного применения
MX2015014351A (es) Compuestos de union a nhe3 (intercambiador de sodio-hidrogeno 3) y metodos para inhibir transporte de fosfato.
PH12019502062A1 (en) Skin barrier composition
MY174747A (en) Bace1 inhibitors
CL2017000845A1 (es) Inhibidores de gingipaina de lisina
UY38345A (es) Composición farmacéutica que comprende agente antiplaquetario e inhibidor de la secreción de ácido g
MX2020001399A (es) Agentes antifungicos con actividad mejorada en ph acido.
MX382601B (es) DERIVADOS DE QUINOXALINA Y PIRIDOPRAZINA COMO INHIBIDORES DE PI3Kß.
MX2017016774A (es) Agente terapeutico para la fibrosis.
MX388592B (es) Compuestos y metodos terapeuticos.
CL2015002817A1 (es) Formulación del l-5-metiltetrahidrofolato de calcio amorfo (l-5-mthf-ca).
MX2018005004A (es) Compuestos de indazol substituidos como inhibidores de rorgammat y sus usos.
JOP20190156B1 (ar) أميدات عطرية لحمض الكربوكسيليك بصفتها مضادات لمستقبلة البراديكينين b1
CL2015001502A1 (es) Composición farmacéutica que comprende desloratadina y prendnisolona y uso de la misma.
MX361880B (es) Composicion antifungica topica para el tratamiento de onicomicosis.
PH12015501210A1 (en) Use of pidotimod to treat psoriasis
PE20190321A1 (es) Composiciones farmaceuticas